Sanofi
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SAN.PA | BIIB | PFE | NVS | GILD | BMY | |
|---|---|---|---|---|---|---|
| Market cap | 86.19B | 34.37B | 168.60B | 286.29B | 193.67B | 122.05B |
| P/E (TTM) | 22.1 | 41.3 | 38.9 | 22.8 | — | 13.2 |
| Forward P/E | 8.0 | 14.1 | 10.2 | 15.4 | 15.7 | 9.0 |
| Price/book | 1.2 | 1.8 | 2.0 | 6.9 | 16.4 | 5.5 |
| Dividend yield | 5.74% | — | 5.81% | 3.15% | 2.10% | 4.22% |
| 1-year change | −16.51% | +58.66% | +19.81% | +14.29% | +26.87% | +37.07% |
| Today | −0.30% | −1.15% | +0.48% | +0.16% | −0.75% | −1.35% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All SAN.PA news ›Recursion Pharmaceuticals: Sanofi News And Fundraising Sum Up Flawed Bull Thesis
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term catalysts. Click for more on RXRX. - Recursion Pharmaceuticals announced a $200m equity offering and a $10m milestone…
Recursion announces $200M equity offering, Sanofi milestone
Recursion wins $200M investment, Sanofi milestone (RXRX:NASDAQ) Seeking Alpha Panama7/iStock Editorial via Getty Images Recursion (RXRX) lost more than 4% in the early premarket trading on Thursday after a $200M equity offering from the…
Sanofi and pCPA Sign Letter of Intent for Dupixent® Across Four Indications in Dermatology and Respiratory Care
Sanofi to work with provinces, territories, and federal drug programs to support patient access through public drug plans "This agreement with the pCPA is an important step forward in expanding patient access to the first advanced biologic…
Sanofi x Tour de France: The Race for Health Is On
Published on: October 16, 2026 On the Tour, determination is never enough on its own. Behind every performance is a team consisting of riders, sports directors, engineers, and analysts with different areas of expertise but united around a…
Recursion prices $200M stock offering as Sanofi picks a partnered drug candidate
Sanofi has optioned the first development candidate to emerge from its research collaboration with Recursion, the Salt Lake City drug discovery company, triggering a $10 million milestone payment the same morning Recursion priced an…
Sanofi Options First Recursion Candidate for $10 Million Milestone
Recursion Pharmaceuticals announced (RXRX ) on October 15, 2026 that Sanofi has optioned the first development candidate from the two companies’ multi-program research collaboration, triggering a US$10 million milestone payment to…
Sanofi clears up years of 'HR tech debt' before scaling AI
Sanofi clears of up years of 'HR tech debt' before scaling AI HR Executive Sanofi clears up years of 'HR tech debt' before scaling AI
New Sanofi facility in Toronto to boost Canada’s flu-vaccine production, pandemic preparedness
October 15, 2026 By Jared Dodds The $925 million expansion is adding end-to-end vaccine manufacturing capacity on Canadian soil Sept. 16, 2026, Toronto — Sanofi today inaugurated the Charles Best Building, a flu-vaccine manufacturing…
Sanofi agrees to stop disparaging rival flu vaccine in EU antitrust settlement
French pharma giant avoids a fine but must correct potentially misleading claims about a competitor’s vaccine and change its promotional practices until 2030. The Commission announced on Wednesday (14 October) that Sanofi must correct…
Antoinette Cordova Begins New Role as Global Medical Director, Stakeholder Engagement in Immunology at Sanofi
Oncodaily Antoinette Cordova Begins New Role as Global Medical Director, Stakeholder Engagement in Immunology at Sanofi Antoinette Cordova, Global Medical Director, Stakeholder Engagement Immunology at Sanofi, shared on LinkedIn: “I’m…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com9
-
seekingalpha.com8
-
firstwordpharma.com4
-
markets.businessinsider.com4
-
statnews.com4
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.